TK008 Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia.

Trial Profile

TK008 Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs TK (Primary) ; T cell replacement therapy
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Graft-versus-host disease
  • Focus Registrational; Therapeutic Use
  • Sponsors MolMed
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Dec 2016 Pooled results from this and other phase II study (profile 700030108) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 05 Dec 2016 Results published in the MolMed Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top